Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-21
2011-06-21
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S360000, C544S362000, C544S405000, C514S252100
Reexamination Certificate
active
07964606
ABSTRACT:
The present invention discloses compounds of formula:where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Phenylene Compound”); compositions comprising an effective amount of a Phenylene Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Phenylene Compound.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5294624 (1994-03-01), Fuse et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5762925 (1998-06-01), Sagen
patent: 5840720 (1998-11-01), Chen
patent: 6136839 (2000-10-01), Isakson et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: 6239267 (2001-05-01), Duckworth et al.
patent: 6326385 (2001-12-01), Wickenden et al.
patent: 6335180 (2002-01-01), Julius et al.
patent: 6406908 (2002-06-01), McIntyre et al.
patent: 6495550 (2002-12-01), McNaughton-Smith et al.
patent: 6974818 (2005-12-01), Kyle et al.
patent: 7772254 (2010-08-01), Sun
patent: 2001/0049444 (2001-12-01), McNaughton-Smith et al.
patent: 2003/0153596 (2003-08-01), Suh et al.
patent: 2004/0259931 (2004-12-01), Goodfellow et al.
patent: 2005/0130954 (2005-06-01), Mitchell et al.
patent: 2005/0222161 (2005-10-01), Moriya et al.
patent: 2005/0222410 (2005-10-01), Stokes et al.
patent: 2006/0100245 (2006-05-01), Bakthavatchalam et al.
patent: 2006/0142333 (2006-06-01), MacDonald et al.
patent: 2006/0235022 (2006-10-01), Sun
patent: 2006/0241117 (2006-10-01), Sun
patent: 2010/0317670 (2010-12-01), Sun
patent: 100 10 422 (2001-09-01), None
patent: 0 533 267 (1993-03-01), None
patent: 2 276 162 (1994-09-01), None
patent: 2 276 163 (1994-09-01), None
patent: WO 94/05153 (1994-03-01), None
patent: WO 98/20867 (1998-05-01), None
patent: WO 00/39117 (2000-07-01), None
patent: WO 03/087057 (2003-10-01), None
patent: WO 2004/056774 (2004-07-01), None
patent: WO 2004/058762 (2004-07-01), None
patent: WO 2004056774 (2004-07-01), None
patent: WO 2004/072069 (2004-08-01), None
patent: WO 2004/106285 (2004-12-01), None
patent: WO 2005/003101 (2005-01-01), None
patent: WO 2005/016323 (2005-02-01), None
Amadji et al., “Chirons in the 1,3-dioxane series: Stereospecific cross-coupling reactions and chirality transfers,”Tetrahedron9:1657-60 (1998).
Bartho et al., “Involvement of capsaicin-sensitive neurones in hyperalgesia and enhanced opioid antinociceptice in inflammation,”Naunyn-Schmiefrnrth's Archives Pharmacol. 342:666-670 (1990).
Berkow et al., “Crohn's Disease,”The Merck Manual of Medical Information528-530 (1997).
Berkow et al., “Irritable Bowel Syndrome,”The Merck Manual of Medical Information525-526 (1997).
Berkow et al., “Peptic Ulcer,”The Merck Manual of Medical Information496-500 (1997).
Berkow et al., “Seizure Disorders,”The Merck Manual of Medical Information, pp. 345-350 (1997).
Berkow et al., “Stroke,”The Merck Manual of Medical Information, pp. 352-355 (1997).
Berkow et al., “Ulcerative Colitis,”The Merck Manual of Medical lrformation530-532 (1997).
Berkow et al., “Urinary Incontinence,”The Merck Manual of Medical Information631-634 (1997).
Bevan et al., “Vanilloid Receptors: Pivotal Molecules in Nocciception,”Current Opinions in CPNS Investigational Drugs 2(2):178-185 (2000).
Billotte, “Synthesis of C-substituted cyclic amines using azacycloalkyl organozinc reagents,”Synlett. pp. 379-380 (Apr. 1998).
Brunton, “Agents for control of gastric acidity and treatment of peptic ulcers,”Goodman and Gilman 's The Pharmacological Basis of Therapeutics, pp. 901-915 (J. Hardman and L. Limbird eds., 9thed. 1996).
Buchwald et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis,”Surgery 88:507-516 (1980).
Chiamulera et al., “Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice,”Nature Neurosci. 4(9):873-874 (2001).
Controlled Drug Bioavailability, Drug Product Design and Performance(Smolen and Ball eds., 1984).
Cooke, “Glycopyrrolate in bladder dysfunction,”SA Medical J. 63:3 (1983).
D'Amour et al., “A method for determining loss of pain sensation,”J. PharmacoL Exp. Ther. 72:74-79 (1941).
Di Marzo et al., “Endovanilloid signaling in pain,”Current Opinion in Neurobiology 12:372-379 (2002).
Dogrul et al., “Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGluR5) antagonist, in experimental neuropathic pain in rats,”Neurosci. Lett. 292(2):115-118 (2000).
During et al., “Controlled release of dopamine from a polymeric brain implant: In vivo characterization,”Ann. Neurol. 25:351-356 (1989).
Fillon et al., “Electrosynthesis of functionalized organodizinc compound from aromatic dihalides via a cobalt catalysis in acetonitrile/pyridine as solvent,”Tett Lett 42:3843-3846 (2001).
Foley, “Pain,”Cecil Textbook cf Medicine, pp. 100-107 (1996).
Fundytus et al.. “Antisense oligonucleotide knockdown of mGluR1alleviates hyperalgesia and allodynia associated with chronic inflammation,”Pharmacol., Biochem. & Behavior 73:401-410 (2002).
Fundytus et al., “In vivoantinociceptive activity of anti-rat mGluR1and mGluR5antibodies in rats,”NeuroReport 9:731-735 (1998).
Fundytus et al., “Knockdown of spinal metabotropic glutamate receptor 1 (mGluR1) alleviates pain and restores opioid efficacy after nerve injury in rats,”Brit J. Pharmacol. 132:354-367 (2001).
Fundytus, “Glutamate receptors and nociception implications for the drug-treatment of pain,”CNS Drugs 15:29-58 (2001).
Goodson, inMedical Applications of Controlled Release, vol. 2, pp. 115-138 (1984).
Greene et al.,Protective Groups in Organic Synthesis, 309-405 (2d ed. 1991).
Greene, “Protection for the hydroxyl group including 1,2- and 1,3-diols,”Protective Groups in Organic Synthesispp. 10-86 (1981).
Grupp et al, “Protection against hypoxia-reoxygenation in the absence of poly (ADP-ribose) synthetase in isolated working hearts,”J. Mol. Cell Cardiol. 31:297-303 (1999).
Hanson, “Analgesic, antipyretic and anti-inflammatory drugs,”Remington: The Science and Practice of Pharmacy Vol. ll, pp. 1196-1221 (A.R. German ed. 19th ed. 1995).
Hargreaves et al, “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia,”Pain 32(1):77-88 (1988).
Howard et al., “Intracerebral drug delivery in rats with lesion-induced memory deficits,”J. Neurosurg. 71:105 (1989).
Insel, “Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout,” inGoodman & Gilman's The Pharmacological Basis of Therapeuticspp. 617-657 (Molinhoff and Ruddon eds., 9thed 1996).
Kim, “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat,”Pain 50:355-363
Dechert LLP
Habte Kahsay T
Purdue Pharma L.P.
LandOfFree
Therapeutic agents useful for treating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents useful for treating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents useful for treating pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2713804